Molecular Cytogenetics (Sep 2017)

A unique set of complex chromosomal abnormalities in an infant with myeloid leukemia associated with Down syndrome

  • Daiane Correa de Souza,
  • Amanda Faria de Figueiredo,
  • Daniela R. Ney Garcia,
  • Elaine Sobral da Costa,
  • Moneeb A.K. Othman,
  • Thomas Liehr,
  • Eliana Abdelhay,
  • Maria Luiza Macedo Silva,
  • Teresa de Souza Fernandez

DOI
https://doi.org/10.1186/s13039-017-0335-3
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background Children with Down syndrome (DS) have an enhanced risk of developing acute leukemia, with the most common subtype being acute megakaryoblastic leukemia (AMKL). Myeloid leukemia in Down syndrome (ML-DS) is considered a disease with distinct clinical and biological features. There are few studies focusing on the clonal cytogenetic changes during evolution of ML-DS. Case presentation Here, we describe a complex karyotype involving a previously unreported set of chromosomal abnormalities acquired during progression of ML-DS in an infant boy: derivative der(1)t(1;15)(q24;q23), translocation t(4;5)(q26;q33) and derivative der(15)t(7;15)(p21;q23). Different molecular cytogenetic probes and probesets including whole chromosome painting (WCP) and locus specific probes, as well as, multicolor-FISH and multicolor chromosome banding (MCB) were performed in order to characterize the chromosomal abnormalities involved in this complex karyotype. The patient was treated according to the acute myeloid leukemia-Berlin-Frankfurt-Munich-2004 (AML-BFM 2004) treatment protocol for patients with Down syndrome; however, he experienced a poor clinical outcome. Conclusion The molecular cytogenetic studies performed, allowed the characterization of novel chromosomal abnormalities in ML-DS and possible candidate genes involved in the leukemogenic process. Our findings suggest that the complex karyotype described here was associated with the poor prognosis.

Keywords